ATHIRA PHARMA INC. - COMMON STOCK

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

29 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND

28 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease

15 Nov 2023 08:15:00 By Nasdaq GlobeNewswire

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates

09 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

Athira Pharma to Participate in Jefferies London Healthcare Conference

08 Nov 2023 07:00:02 By Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

05 Oct 2023 16:30:00 By Nasdaq GlobeNewswire

Athira Pharma to Participate in Upcoming October Conferences

28 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

19 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

10 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease

17 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023

06 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma to Participate in Upcoming June Conferences

31 May 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

22 May 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates

11 May 2023 16:05:01 By Nasdaq GlobeNewswire

Athira Pharma to Participate in Upcoming May Investor Conferences

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

25 Apr 2023 16:01:00 By Nasdaq GlobeNewswire

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

11 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference

28 Mar 2023 01:00:00 By Nasdaq GlobeNewswire